1. Targeted 8-arm PEG Nanosystems for Localization of Choroidal Neovascularization Macular Degeneration Model.
- Author
-
McLean A, Zhang W, Cooke A, Potter NS, Kopelman R, and Paulus YM
- Subjects
- Animals, Mice, Disease Models, Animal, Materials Testing, Biocompatible Materials chemistry, Biocompatible Materials pharmacology, Humans, Oligopeptides chemistry, Mice, Inbred C57BL, Choroidal Neovascularization drug therapy, Choroidal Neovascularization pathology, Choroidal Neovascularization metabolism, Polyethylene Glycols chemistry, Macular Degeneration drug therapy, Macular Degeneration pathology, Particle Size, Nanoparticles chemistry
- Abstract
8-arm PEG (polyethylene-glycol) is a highly promising nanoplatform due to its small size (<10 nm), ease-of-conjugation (many functionalized variants are readily available with "click-like" properties), biocompatibility, and optical inactivity. This study evaluates 8-arm PEG uptake into cells ( in vitro ) and localization and clearance in vasculature ( in vivo ) for targeting of choroidal neovascularization in mice, an animal model of macular degeneration. 8-arm PEG nanoparticles were labeled with fluorescein isothiocyanate (FITC) and functionalized in the absence or presence of pentameric Ar-Gly-Asp (RGD; 4 RGD motifs and a PGC linker), one of the most common peptide motifs used for active targeting. In vitro studies show that RGD-conjugated 8-arm PEG nanoparticles exhibit enhanced cellular uptake relative to non-RGD-conjugated control NPs at 34% ± 9%. Laser-induced choroidal neovascularization (CNV) was performed in a mouse model to measure 8-arm PEG localization and clearance to model macular degeneration lesions in vivo . It was determined that both RGD-conjugated and non-RGD-conjugated (nRGD) 8-arm PEG particles localized to CNV lesions, with a half-life around 24 h. In vivo experiments showed that RGD-conjugated nanoparticles exhibited enhanced localization by 15-20% relative to without RGD controls. Exhibiting a high rate of localization and fast clearance relative to larger nanoparticles, targeted 8-arm PEG nanoparticles with a conjugated RGD-peptide could be a promising modality for macular degeneration diagnosis and therapy.
- Published
- 2024
- Full Text
- View/download PDF